We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at ...

The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

Goldman has recently reduced Moderna Inc (MRNA) stock to Neutral rating, as announced on January 29, 2025, according to Finviz. Earlier, on December 18, 2024, Argus had reduced the stock from a Buy to ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $45 from $55 and keeps a Market Perform rating on the shares. The firm cites the ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...